Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436129 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL1001473 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL19661184 | 0.92 | TLR2 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL9288118 | 0.91 | KMT2A (0.51) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL14432835 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL14788958 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL800305 | 0.89 | FDFT1 (0.57) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL1486194 | 0.89 | SLC17A5 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL4600701 | 0.89 | FDFT1 (0.57) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL800035 | 0.89 | FDFT1 (0.57) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039383-A | Preparation method of leuprorelin impurity K | 深圳市健元医药科技有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-115819511-A | Preparation method and application of giant salamander hydrolyzed collagen active peptide | 广州远想医学生物技术有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-119039383-A | Preparation method of leuprorelin impurity K | 深圳市健元医药科技有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118772247-A | PKal bicyclic peptide and application thereof in medicine | 西藏海思科制药有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2024-01-11 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230157302-A1 | METHODS FOR INHIBITING FUSARIUM MYCOTOXIN PRODUCTION | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2023-05-25 | — | — | US | disclosed |
| CN-116063461-A | Skin repair peptide and application thereof | 广州远想医学生物技术有限公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| CN-115819511-A | Preparation method and application of giant salamander hydrolyzed collagen active peptide | 广州远想医学生物技术有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4139336-A1 | METHODS FOR INHIBITING FUSARIUM MYCOTOXIN PRODUCTION | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (FR) | 2023-03-01 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-4011904-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SPINT2, SERPINB1 | MDM4 3411/4885TP53 2928/4885CASP3 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.